Gufic Biosciences Launches 'Saksham Niveshak' Campaign for Unclaimed Dividends
Gufic Biosciences launched the 'Saksham Niveshak' campaign from July 28 to November 06, 2025, to help shareholders claim unpaid dividends and update KYC details, as requested by IEPFA.
The campaign is an administrative and regulatory compliance initiative aimed at investor awareness and facilitation. It is not expected to have a material financial or operational impact on the company's core business.
The announcement details a compliance-driven campaign to assist shareholders with unclaimed dividends and KYC updates. While beneficial for investors, it does not indicate a direct positive or negative financial impact on the company.
Gufic Biosciences Limited has initiated the "Saksham Niveshak" campaign, running from July 28, 2025, to November 06, 2025. This campaign, launched at the request of the Investor's Education and Protection Fund Authority (IEPFA) and the Ministry of Corporate Affairs (MCA) via an intimation dated July 16, 2025, aims to facilitate shareholders in claiming their unpaid or unclaimed dividends and updating their KYC details. * The company previously sent letters on July 07, 2025, to shareholders whose unpaid/unclaimed dividends and shares for the financial year 2017-18 are due for transfer to the IEPF. * Shareholders holding physical shares are required to update their KYC details, including PAN, contact information, bank account details, and signature, by submitting Investor Service Request (ISR) Forms (ISR-1, ISR-2, ISR-3/SH-13) to the company's Registrar and Transfer Agent (RTA). This is crucial as dividends from April 01, 2024, are only disbursed electronically for KYC-updated folios, as per SEBI Master Circular dated June 23, 2025. * Shareholders with demat accounts can claim their unclaimed dividends by updating their details with their respective Depository Participants (DPs). * For any assistance regarding the "Saksham Niveshak" campaign, shareholders can contact MUFG Intime India Private Limited, the company's RTA.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under investor complaints. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.